|
The timing of chemoradiotherapy after surgical resection and its impact on overall survival in glioblastoma. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Nanthealth |
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb |
Research Funding - Abbvie (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Varian Medical Systems |
Speakers' Bureau - Varian Medical Systems |
Travel, Accommodations, Expenses - Varian Medical Systems |
|
|
No Relationships to Disclose |